ArticleTransplantation direct2015
A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates.
Article in Transplantation direct, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Clinical outcomes of bortezomib-based desensitization in highly sensitized living and deceased donor kidney transplantation.Kidney research and clinical practice · 2026Article
- Systematic Review of Bortezomib-based Desensitization Therapy in Sensitized Kidney Transplant Candidates: Efficacy, Safety, and Clinical Outcomes.Journal of research in pharmacy practice · 2026Article
- Article
- Time-unrestricted, Immune Surveillance-Guided Desensitization Enables Kidney Transplantation in Highly Sensitized Patients.Kidney international reports · 2026Article
- Donor-recipient HLA molecular mismatch and T follicular helper-related genetic variants are associated with dnDSA development after kidney transplantation.Frontiers in immunology · 2026Article
- Potential of Kidney Exchange Programs (KEPs) in Japan for Donor-Specific Antibody-Positive Kidney Transplants: A Questionnaire Survey on KEPs and a Multi-Institutional Study Conducting Virtual Cross-Matching Simulations.Journal of clinical medicine · 2025Article
- The impact of preformed donor-specific antibodies in living donor liver transplantation according to graft volume.Immunity, inflammation and disease · 2022Article
- Case report: Successful simultaneous heart-kidney transplantation across a positive complement-dependent cytotoxic crossmatch.Frontiers in nephrology · 2022Article
- B cell depletion with anti-CD20 mAb exacerbates anti-donor CD4Scientific reports · 2021Article
- Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis.Scientific reports · 2021Article
- Detection of Antibodies Against Human Leukocyte Antigen Class II in the Sera of Patients Receiving Intravenous Immunoglobulin.Transplantation direct · 2021Article
- Contemporary Strategies and Barriers to Transplantation Tolerance.Transplantation · 2018Review
- Successful Kidney Transplantation After Stepwise Desensitization Using Rituximab and Bortezomib in a Highly HLA-Sensitized and ABO Incompatible High Titer Patient.Transplantation direct · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledDesensitization protocols comprising plasmapheresis, IVIGs, and rituximab and/or bortezomib have allowed for successful kidney transplantation in some highly HLA-sensitized patients with end-stage renal disease. However, the optimal combination of these therapies and their proper timing remains entirely unknown. We propose a phased desensitization strategy using rituximab followed by bortezomib as a safer method.
methodsThree sensitized kidney transplant candidates who could not be desensitized using our conventional protocol, which consists of a single rituximab dose combined with plasmapheresis, were enrolled in this study. When IgM(+) CD27(-) naive B cells reappeared but IgM(+) CD27(+) memory B cells remained undetectable in their peripheral blood, the patients were treated with 1 cycle of bortezomib followed by plasmapheresis.
resultsAfter bortezomib treatment, patients' donor-specific anti-HLA antibodies (DSA) values were decreased, and cross-match tests were consistently negative. All 3 patients underwent living donor kidney transplantation. They showed immediate renal function, and both DSA and non-DSA were undetectable during the observation period. Neither antibody-mediated rejection nor severe acute cellular rejection was encountered in these patients after transplantation.
conclusionsThe present cases suggest that a phased use of rituximab and bortezomib can safely desensitize highly sensitized kidney transplant candidates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.